Adlai Nortye (NASDAQ:ANL) is a global biopharmaceutical company focused on developing innovative treatments in oncology. With a dedication to pushing the boundaries of science to improve patient outcomes, Adlai Nortye is actively engaged in researching and developing therapies that target various stages of cancer. The company's projects span from early discovery to late-stage development, aiming to bring new solutions to unmet medical needs in the cancer treatment landscape. Operating globally, Adlai Nortye's mission revolves around advancing cancer care through groundbreaking research, strategic collaborations, and effective development of its therapeutic pipeline, striving to offer better, more effective treatments to patients around the world.